Abstract
Ehlers–Danlos syndrome (EDS) is an emerging cause of skeletal fragility. Mechanism of bone damage are probably multifactorial in line with the different skeletal phenotypes that can be found in clinical practice. A structured approach to clinical management of bone metabolic complication in EDS is proposed.
Similar content being viewed by others
References
B. Steinmann, P.M. Royce, A. Superti-Furga, in: Connective Tissue and Its Heritable Disorders, ed. by P.M. Royce, B. Steinmann (Wiley-Liss: New York, NY, USA, 2002), pp. 431–524
F. Malfait, C. Francomano, P. Byers, J. Belmont, B. Berglund et al. The 2017 international classification of the Ehlers–Danlos syndromes. Am. J. Med. Genet. 175C, 8–26 (2017)
M. Colombi, C. Dordoni, N. Chiarelli, M. Ritelli, Differential diagnosis and diagnostic flow chart of joint hypermobility syndrome/Ehlers–Danlos syndrome hypermobility type compared to other heritable connective tissue disorders. Am. J. Med. Genet. 169, 6–22 (2015)
M. Ritelli, M. Venturini, C. Dordoni, N. Chiarelli, S. Quinzani et al. Clinical and molecular characterization of 40 patients with classic Ehlers-Danlos syndrome: identification of 18 COL5A1 and 2 COL5A2 novel mutations. Orphanet. J. Rare. Dis. 8, 58 (2013)
M. Colombi, C. Dordoni, M. Venturini, C. Ciaccio, S. Morlino et al. Spectrum of mucocutaneous, ocular and facial features and delineation of novel presentations in 62 classical Ehlers-Danlos syndrome patients. Clin. Genet. 92, 624–631 (2017)
M. Castori, B. Tinkle, H. Levy, R. Grahame, F. Malfait, A. Hakim, A framework for the classification of joint hypermobility and related conditions. A continuous spectrum of phenotypes exists grouping together patients with isolated, non-syndromic joint hypermobility, HSD and hEDS. Am. J. Med. Genet. C. Semin. Med. Genet. 175(1), 148–157 (2017)
M. Castori, A. Hakim, Contemporary approach to joint hypermobility and related disorders. Curr. Opin. Pediatr. 29(6), 640–649 (2017)
Y. Gazit, G. Jacob, R. Grahame, Ehlers–Danlos syndrome—hypermobility type: a much neglected multisystemic disorder. Rambam Maimonides Med 7, 1–10 (2016)
A.A. Deodhar, A.D. Woolf, Ehlers-Danlos syndrome and osteoporosis. Ann. Rheum. Dis. 53, 841–842 (1994)
P.C. Coelho, R. Santos, J.A. Gomes, Osteoporosis and Ehlers-Danlos syndrome. Ann. Rheum. Dis. 53, 212–213 (1994)
A.L. Dolan, N.K. Arden, R. Grahame, T.D. Spector, Assessment of bone in Ehlers Danlos syndrome by ultrasound and densitometry. Ann. Rheum. Dis. 57, 630–633 (1998)
G. Mazziotti, C. Dordoni, M. Doga, F. Galderisi et al. High prevalence of radiological vertebral fractures in adult patients with Ehlers–Danlos syndrome. Bone 84, 88–92 (2016)
C. Eller-Vainicher, A. Bassotti, A. Imeraj, E. Cairoli et al. Bone involvement in adult patients affected with Ehlers-Danlos syndrome. Osteoporos. Int. 27, 2525–2531 (2016)
S. Bonadonna, G. Mazziotti, M. Nuzzo, A. Bianchi et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J. Bone Miner. Res. 30, 1837–1844 (2005)
G. Mazziotti, M. Doga, S. Frara, F. Maffezzoni et al. Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52, 103–110 (2016)
G. Mazziotti, A. Delgado, F. Maffezzoni, A. Formenti et al. Skeletal fragility in endogenous hypercortisolism. Front. Horm. Res. 46, 66–73 (2016)
P. Beighton, A. De Paepe, B. Steinmann, P. Tsipouras et al. Ehlers–Danlos syndromes: revised nosology, Villefranche, 1997. Ehlers–Danlos National Foundation (USA) and Ehlers–Danlos Support Group (UK). Am. J. Med. Genet. 77, 31–37 (1998)
J.T. Schousboe, J.A. Shepherd, J.P. Bilezikian et al. Executive summary of the2013 International Society for Clinical Densitometry position development conference on bone densitometry. J. Clin. Densitom. 16, 455–466 (2013)
J.F. Griffith, H.K. Genant, New advances in imaging osteoporosis and its complications. Endocrine 42, 39–51 (2012)
R.T. Franceschi, The developmental control of osteoblast specific gene expression: role of specific transcription factors and the extracellular matrix environment. Crit. Rev. Oral. Biol. Med. 10, 40–57 (1999)
C. Ge, Q. Yang, G. Zhao, H. Yu et al. Interactions between extracellular signal-regulated kinase 1/2 and p38 MAP kinase pathways in the control of RUNX2 phosphorylation and transcriptional activity. J. Bone Miner. Res. 27, 538–551 (2012)
G.S. Schultz, J.M. Davidson, R.S. Kirsner, P. Bornstein et al. Dynamic reciprocity in the wound microenvironment. Wound Rep. Reg. 19, 134–148 (2011)
T. Palomo, T. Vilaça, M. Lazaretti-Castro, Osteogenesis imperfecta: diagnosis and treatment. Curr. Opin. Endocrinol. Diabetes Obes. 24, 381–388 (2017)
M. Fiscaletti, C.P. Coorey, A. Biggin, J. Briody, Diagnosis of recurrent fractures in a pediatric cohort. Calcif. Tissue Int. 103(5), 529–539 (2018). https://doi.org/10.1007/s00223-018-0449-6
J. Lim, I. Grafe, S. Alexander, B. Lee, Genetic causes and mechanisms of osteogenesis imperfecta. Bone 102, 40–49 (2017)
N. Chiarelli, G. Carini, N. Zoppi, C. Dordoni, M. Ritelli, M. Venturini, M. Castori, M. Colombi, Transcriptome-wide expression profiling in skin fibroblasts of patients with joint hypermobility syndrome/Ehlers–Danlos syndrome hypermobility type. PLoS ONE 11(8), e0161347 (2016)
N. Zoppi, N. Chiarelli, S. Binetti, M. Ritelli, M. Colombi, Dermal fibroblast-to-myofibroblast transition sustained by αvß3 integrin-ILK-Snail1/Slug signaling is a common feature for hypermobile Ehlers–Danlos syndrome and hypermobility spectrum disorders. Biochem Biophys. Acta 1864(4 Pt A), 1010–1023 (2018)
S. Shuster, Osteoporosis, a unitary hypothesis of collagen loss in skin and bone. Med. Hypotheses 65, 426–432 (2005)
L. Carbone, F.A. Tylavsky, A.J. Bush, W. Koo et al. Bone density in Ehlers–Danlos syndrome. Osteoporos. Int. 11, 388–392 (2000)
M.F. Holick, A. Hossein-Nezhad, F. Tabatabaei, Multiple fractures in infants who have Ehlers–Danlos/hypermobility syndrome and or vitamin D deficiency: a case series of 72 infants whose parents were accused of child abuse and neglect. Dermatoendocrinol 9(1), e1279768 (2017). https://doi.org/10.1080/19381980.2017.1279768
M. Yamashita, K. Hasegawa, Y. Higuchi, T. Miyai et al. Urinary cross-linked N-terminal telopeptide of type I collagen levels of infants with Osteogenesis Imperfecta and healthy infants. Acta Med. Okayama 70, 435–439 (2016)
E. Aström, P. Magusson, S. Eksborg, S. Söderhäll, Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with Osteogenesis Imperfecta. Acta Paediatr. 99, 1834–1840 (2010)
G. Mazziotti, A.M. Formenti, S. Frara, R. Olivetti et al. High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma. J. Clin. Endocrinol. Metab. 103, 956–964 (2017)
D. Diacinti, D. Pisani, M. D”Avanzo, M. Celli et al. Reliability of vertebral fractures assessment (VFA) in children with Osteogenesis Imperfecta. Calcif. Tissue 96, 307–312 (2015)
C. Grey, R. Young, P.W. Bearcroft, J.E. Compston, Vertebral deformity in the thoracic spine in post-menopausal women: value of lumbar spine bone density. Br. J. Radiol. 69, 137–42 (1996)
G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41, 58–69 (2012)
G. Mazziotti, S. Frara, A. Giustina, Pituitary diseases and bone. Endocr. Rev. 39, 440–488 (2018). https://doi.org/10.1210/err.2018-00005
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
A.G. is consultant for Abiogen. The remaining authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any experimental studies with human participants performed by any of the authors. Data collected from routine evaluation of two patients are reported.
Informed consent
Informed consent was obtained from the two patients whose routine data were reported in the manuscript.
Rights and permissions
About this article
Cite this article
Formenti, A.M., Doga, M., Frara, S. et al. Skeletal fragility: an emerging complication of Ehlers–Danlos syndrome. Endocrine 63, 225–230 (2019). https://doi.org/10.1007/s12020-018-1822-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-018-1822-y